Jeito Capital Closes Record $1.2B Europe-Focused Biopharma Fund

Why It Matters

The fund provides scarce long‑term capital to European biotech, potentially accelerating drug development and keeping innovation on the continent, while offering investors exposure to high‑growth therapeutic assets.

Key Takeaways

• €1bn fund sets record for independent European biopharma investors
• Investment cap raised to €150m per company, enabling larger projects
• Jeito’s AUM tripled to €1.6bn, reflecting rapid growth
• Past exits include $3bn EyeBio sale and $1.8bn HI‑Bio deal

Pulse Analysis

The European biopharma sector has been grappling with a tightening capital environment. Global financing is projected to fall to $75 billion this year, down sharply from the $152 billion peak in 2020, and Europe’s share has slipped to roughly €11 billion (about $12 billion), or 15 % of the total. Despite the funding gap, the continent remains rich in scientific talent and early‑stage pipelines, especially in areas such as oncology, immunology and metabolic disease. Investors therefore view dedicated funds as a critical bridge between discovery and commercialization.

Jeito Capital’s €1 billion second fund, Jeito II, directly addresses that bridge. By expanding the per‑company ceiling to €150 million—almost double the previous limit—the firm can sustain longer development cycles and de‑risk later‑stage trials. The fund’s mandate to back 15‑20 clinical‑stage companies aligns with Jeito’s “patient‑driven” approach, leveraging multidisciplinary expertise from science to market launch. 8 billion sale to Biogen, demonstrate the firm’s ability to generate outsized returns while advancing therapeutic innovation. S.

and Chinese biotech ecosystems. A larger, well‑capitalized fund can attract top‑tier talent, accelerate drug pipelines, and ultimately contribute to regional economic growth through job creation and exportable medicines. As the market rebounds, Jeito’s model may inspire similar vehicles, fostering a more resilient financing landscape that supports breakthrough therapies from the lab to the clinic. Stakeholders should watch how this influx of growth capital reshapes the European drug development timeline.

Deal Summary

France-based Jeito Capital has closed its second fund, raising €1 billion ($1.2 billion), the largest ever for an independent European biopharma fund. The Jeito II fund will back 15‑20 clinical‑stage biopharma companies across Europe, with investment caps up to €150 million per company.